Despite global declines in liver cancer mortality attributed to hepatitis B and C, liver cancer mortality rose sharply in the Americas, driven by an increase in nonalcoholic steatohepatitis, according ...

A therapeutic being tested for nonalcoholic steatohepatitis (NASH) and liver fibrosis showed statistically significant improvement versus placebo on two primary endpoints in a one-year, Phase 2b trial ...

The unmet need in non-alcoholic steatohepatitis (NASH) is getting bigger and bigger. In the decade up to 2032, the number of diagnosed cases in seven major markets is forecast to grow by 4.5 million, ...

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no current cure, but a drug called resmetirom may offer a lifeline for millions of patients, promoting a better quality of life ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Loomba: BIO89-100 is being developed and investigated ...

Pharmacotherapies used in the treatment of nonalcoholic steatohepatitis (NASH) were compared in a recent systematic review and network meta-analysis published in Alimentary Pharmacology & Therapeutics ...

KANSAS CITY, Mo. — Doctors and researchers at St. Luke’s Hospital are raising awareness about Non-alcoholic Steatohepatitis, also known as NASH. It is a form of fatty liver disease which occurs when ...

WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and ...

Liver disease researchers, stumped by a complex disease, are looking for new investigative tools. Artificial intelligence might be one of them. At a small conference of the American Association for ...

According to preliminary results released Tuesday, the Akero drug efruxifermin led to at least one stage of improvement in a measure of fibrosis, or liver scarring, that develops from the fatty liver ...